Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Pediatr Infect Dis J ; 40(12): e491-e492, 2021 12 01.
Article in English | MEDLINE | ID: covidwho-1354319


Multisystem inflammatory syndrome in children is a rare, potentially life-threatening postinfectious complication in children after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. It is currently unknown if multisystem inflammatory syndrome in children (MIS-C) can recur upon reinfection with SARS-CoV-2. Here, we report on a former MIS-C patient who was reinfected with SARS-CoV-2 without recurrence of MIS-C.

COVID-19/complications , SARS-CoV-2 , Systemic Inflammatory Response Syndrome/complications , Adolescent , Biomarkers , Female , Humans , Immunoglobulins, Intravenous/therapeutic use , Inflammation/blood , Inflammation/metabolism , Methylprednisolone/therapeutic use , Prednisone/therapeutic use , Recurrence , Reinfection
Pediatr Pulmonol ; 56(8): 2495-2502, 2021 08.
Article in English | MEDLINE | ID: covidwho-1260566


BACKGROUND: Long-COVID is a well-documented multisystem disease in adults. Far less is known about long-term sequelae of COVID in children. Here, we report on the occurrence of long-COVID in Dutch children. PATIENTS AND METHODS: We conducted a national survey asking Dutch pediatricians to share their experiences on long-COVID in children. We furthermore describe a case series of six children with long-COVID to explore the clinical features in greater detail. RESULTS: With a response rate of 78% of Dutch pediatric departments, we identified 89 children, aged 2-18 years, suspected of long-COVID with various complaints. Of these children, 36% experienced severe limitations in daily function. The most common complaints were fatigue, dyspnea, and concentration difficulties with 87%, 55%, and 45% respectively. Our case series emphasizes the nonspecific and broad clinical manifestations seen in post-COVID complaints. CONCLUSION: Our study shows that long-COVID is also present in the pediatric population. The main symptoms resemble those previously described in adults. This novel condition demands a multidisciplinary approach with international awareness and consensus to aid early detection and effective management.

COVID-19 , Adult , COVID-19/complications , Child , Dyspnea , Fatigue/epidemiology , Fatigue/etiology , Humans , SARS-CoV-2 , Post-Acute COVID-19 Syndrome
Endocrine ; 71(3): 653-662, 2021 03.
Article in English | MEDLINE | ID: covidwho-1053106


This article aims to provide guidance on prevention and treatment of COVID-19 in patients with genetic obesity. Key principals of the management of patients with genetic obesity during COVID-19 pandemic for patients that have contracted COVID-19 are to be aware of: possible adrenal insufficiency (e.g., POMC deficiency, PWS); a more severe course in patients with concomitant immunodeficiency (e.g., LEP and LEPR deficiency), although defective leptin signalling could also be protective against the pro-inflammatory phenotype of COVID-19; disease severity being masked by insufficient awareness of symptoms in syndromic obesity patients with intellectual deficit (in particular PWS); to adjust medication dose to increased body size, preferably use dosing in m2; the high risk of malnutrition in patients with Sars-Cov2 infection, even in case of obesity. Key principals of the obesity management during the pandemic are to strive for optimal obesity management and a healthy lifestyle within the possibilities of the regulations to prevent weight (re)gain and to address anxiety within consultations, since prevalence of anxiety for COVID-19 is underestimated.

COVID-19 , Disease Management , Obesity/therapy , Pandemics , Anxiety , Healthy Lifestyle , Humans , Obesity/epidemiology , Obesity/genetics